Physician profile
Ginger S Mentz
NPI 1306018213
$4,300.85
in general payments reported to CMS, 2019-2025
27 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $135 · 2021: $14.82 · 2022: $388 · 2023: $965 · 2024: $839 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.08 |
| Education | $246.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.24 | 2019-2025 | |
| Janssen Biotech, INC. | $588.29 | 2019-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $391.71 | 2019-2024 | Ilumya, Winlevi, Blu-U |
| Novartis Pharmaceuticals Corporation | $358.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $259.77 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $222.64 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $217.81 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $216.70 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $176.95 | 2019-2025 | Bimzelx |
| Incyte Corporation | $173.56 | 2022-2025 | Opzelura |
| Pfizer INC. | $171.19 | 2022-2025 | |
| Genzyme Corporation | $167.30 | 2019-2025 | |
| Galderma Laboratories, L.P. | $90.95 | 2019-2025 | |
| Leo Pharma INC. | $79.52 | 2022-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.47 | 2019-2025 | Siliq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $56.95 | 2022-2024 | |
| Arcutis Biotherapeutics, INC. | $53.47 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $50.81 | 2019 | |
| Celgene Corporation | $41.61 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $41.49 | 2019-2021 | |
| Organon LLC | $41.27 | 2025 | Vtama |
| Convatec INC. | $27.73 | 2025 | |
| Aclaris Therapeutics, INC. | $26.82 | 2019 | |
| Allergan, INC. | $22.63 | 2020 | |
| Blueprint Medicines Corporation | $20.52 | 2024 | Ayvakit |
| Mylan Pharmaceuticals INC. | $20.12 | 2019 | |
| Biofrontera INC. | $16.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Mentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.